fsl 1

TLR2/6 agonist (also a putative TLR10 ligand). Activates NF-κB. Induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. Synergizes with IFNγ to induce CXCL10 release from melanoma cells.

FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection[1]. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2]. FSL-1 significantly reduces HSV-2 replication in human vaginal epithelial cells (EC)[1].FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile[1].FSL-1 (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells[2].FSL-1 activates the MAP kinase/NF-κB signaling pathway[2]. Cell Viability Assay[1] Cell Line: V11I, V12I or V19I immortalized human vaginal EC FSL-1 application significantly protectes against genital HSV-2 challenge in mice[1]. Animal Model: Female Swiss-Webster mice (weighing 20-25 g)[1] [1]. William A Rose 2nd, et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J. 2009 Nov 10;6:195. [2]. Cathryn J Kurkjian,et al. The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome. Sci Rep. 2017 Dec 11;7(1):17355.

NCI 126224 是一种 Toll 样受体 4（TLR4）拮抗剂，可选择性抑制 LPS 诱导的 RAW 264.7 巨噬细胞中一氧化氮生成（IC50 = 0.31 µM），而对 TLR7/8 激动剂 R-848、TLR1/2 激动剂 Pam3CSK4 及 TLR3 激动剂 poly(I:C) 的作用较弱。NCI 126224 在 0.6 µM 条件下抑制 FSL-1 诱导的 NO 生成，并在 BV-2 胶质细胞中抑制 LPS 诱导的 NF-κB 活性，同时降低 RAW 264.7 细胞中 IL-1β 和 TNF-α 水平（IC50 分别为 5.92 µM 和 1.54 µM），显示其在炎症及先天免疫信号通路研究中的重要价值。